ADC Therapeutics (ADCT) said late Monday it has completed patient enrollment in its phase 3 confirmatory trial of Zynlonta in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.

"We anticipate sharing topline results of the primary endpoint analysis by the end of 2025 once the pre-specified number of events is reached and potentially submitting our supplemental BLA to the US Food and Drug Administration in the first quarter of 2026," said Chief Medical Officer Mohamed Zaki.